Acute gastroenteritis is a leading cause of illness and death in young children worldwide. Before rotavirus vaccines, rotavirus was the leading cause of severe pediatric gastroenteritis, infecting nearly all children by age 5 years and causing 500,000 deaths annually worldwide. In 1998, RotaShield® (Wyeth Lederle Vaccines SA, Louvain-la-Neuve, Belgium), the first rotavirus vaccine, was licensed and recommended, then withdrawn from the market after a year due to an elevated risk of intussusception. Rotavirus vaccines were unavailable until 2006, when Merck & Co (Rahway, NJ) introduced the 3-dose RotaTeq® vaccine. In 2008, GlaxoSmithKline (Philadelphia, PA) introduced the 2-dose Rotarix® vaccine. More recently, Rotasiil (Serum Institute of India Pvt Ltd, Pune, India) and Rotavac® (Bharat Biotech Ltd, Hyderabad, India) obtained World Health Organization prequalification. Rotavirus vaccination, which reached 50% global coverage in 2020, resulted in 40% reductions in all-cause child mortality among target populations in high-burden settings. Since then, 2 caliciviruses—norovirus and...
Skip Nav Destination
Article navigation
March 2023
In Brief|
March 01 2023
Post–Rotavirus Vaccine Enteropathogen Landscape
Sarah-Blythe Ballard, MD, PhD, MPH;
Sarah-Blythe Ballard, MD, PhD, MPH
*Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Search for other works by this author on:
Robert H. Gilman, MD, DTM&H
Robert H. Gilman, MD, DTM&H
*Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Search for other works by this author on:
Pediatr Rev (2023) 44 (3): 182–184.
Citation
Sarah-Blythe Ballard, Robert H. Gilman; Post–Rotavirus Vaccine Enteropathogen Landscape. Pediatr Rev March 2023; 44 (3): 182–184. https://doi.org/10.1542/pir.2022-005565
Download citation file:
Sign in
Don't already have an account? Register
Pay-Per-View Access
$35.00
351
Views
Comments